An Open-Label, FIH Study Evaluating the Safety, Tolerability, and Efficacy of VCTX211 Combination Product in Subjects With T1D

Phase 1 Terminated 5 enrolled CRISPR Therapeutics AG ViaCyte · collab

NaSingle-groupOpen-labelTreatment

Summary

This is an open-label, multicenter, Phase 1 study evaluating the Safety, Tolerability, and Efficacy of VCTX211 Combination Product in Subjects with T1D

Timeline

Start: 2023-01-20
Primary completion: 2025-08-08
Completion: 2025-08-08

Outcome

Outcome not reported

Stopped: “Patients to be followed up in the VCTX-201 study”

Publications

Lin TM, Chang HF, Lin TC, Lin CH, Sun YL, Lin CS. Gene Therapy and Gene Editing in Type 1 Diabetes: CRISPR-Based beta-Cell Replacement and Treg Immune Modulation Approaches. Diabetes Obes Metab. 2026 Jul;28(7):5476-5491. doi: 10.1111/dom.70800. Epub 2026 Apr 23.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	VCTX211	Unknown	—	—